Found: 48
Select item for more details and to access through your institution.
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-97366-5
- By:
- Publication type:
- Article
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 9, p. 1234, doi. 10.1111/apt.18228
- By:
- Publication type:
- Article
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 3, p. 463, doi. 10.1111/apt.16937
- By:
- Publication type:
- Article
Systematic review: disease activity indices for immune checkpoint inhibitor‐associated enterocolitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 2, p. 178, doi. 10.1111/apt.16718
- By:
- Publication type:
- Article
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 10, p. 1574, doi. 10.1111/apt.16083
- By:
- Publication type:
- Article
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 568, doi. 10.1111/apt.15919
- By:
- Publication type:
- Article
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
- Published in:
- Pharmaceutical Research, 2017, v. 34, n. 8, p. 1556, doi. 10.1007/s11095-017-2150-2
- By:
- Publication type:
- Article
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
- Published in:
- Drugs, 2021, v. 81, n. 2, p. 333, doi. 10.1007/s40265-020-01460-3
- By:
- Publication type:
- Article
Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.
- Published in:
- Drugs, 2017, v. 77, n. 4, p. 379, doi. 10.1007/s40265-017-0719-z
- By:
- Publication type:
- Article
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.
- Published in:
- Drugs, 2017, v. 77, n. 4, p. 363, doi. 10.1007/s40265-017-0693-5
- By:
- Publication type:
- Article
Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 3, p. 1141, doi. 10.1111/bcp.14479
- By:
- Publication type:
- Article
Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, n. 2, p. 73, doi. 10.1093/jcag/gwaa003
- By:
- Publication type:
- Article
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review.
- Published in:
- Digestive Diseases & Sciences, 2022, v. 67, n. 4, p. 1128, doi. 10.1007/s10620-021-06948-w
- By:
- Publication type:
- Article
Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
- Published in:
- Digestive Diseases & Sciences, 2021, v. 66, n. 10, p. 3563, doi. 10.1007/s10620-020-06669-6
- By:
- Publication type:
- Article
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.
- Published in:
- Crohn's & Colitis 360, 2021, v. 3, n. 3, p. 1, doi. 10.1093/crocol/otab035
- By:
- Publication type:
- Article
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, p. S39, doi. 10.1002/jcph.374
- By:
- Publication type:
- Article
Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 4, p. 743, doi. 10.1111/cts.12760
- By:
- Publication type:
- Article
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 11, p. 1031, doi. 10.1111/apt.15719
- By:
- Publication type:
- Article
Prevalence of endoscopic improvement and remission according to patient‐reported outcomes in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 4, p. 435, doi. 10.1111/apt.15577
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 8, p. 848, doi. 10.1111/apt.15484
- By:
- Publication type:
- Article
Editorial: assessing histological disease activity in Crohn's disease—a call for standardisation of mucosal biopsy location. Authors' reply.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 50, n. 1, p. 5, doi. 10.1111/apt.15297
- By:
- Publication type:
- Article
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 11, p. 1401, doi. 10.1111/apt.15250
- By:
- Publication type:
- Article
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
- Published in:
- PLoS ONE, 2018, v. 13, n. 5, p. 1, doi. 10.1371/journal.pone.0195123
- By:
- Publication type:
- Article
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820971214
- By:
- Publication type:
- Article
Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease – What the Clinician Needs to Know.
- Published in:
- Journal of Crohn's & Colitis, 2022, v. 16, n. 3, p. 460, doi. 10.1093/ecco-jcc/jjab169
- By:
- Publication type:
- Article
Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
- Published in:
- Journal of Crohn's & Colitis, 2022, v. 16, n. 2, p. 224, doi. 10.1093/ecco-jcc/jjab135
- By:
- Publication type:
- Article
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
- Published in:
- Journal of Crohn's & Colitis, 2020, v. 14, p. S725, doi. 10.1093/ecco-jcc/jjaa014
- By:
- Publication type:
- Article
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
- Published in:
- Journal of Crohn's & Colitis, 2019, v. 13, n. 10, p. 1248, doi. 10.1093/ecco-jcc/jjz050
- By:
- Publication type:
- Article
Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Journal of Crohn's & Colitis, 2019, v. 13, n. 9, p. 1201, doi. 10.1093/ecco-jcc/jjz087
- By:
- Publication type:
- Article
Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 11, p. 1379, doi. 10.1093/ecco-jcc/jjy082
- By:
- Publication type:
- Article
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 6, p. 635, doi. 10.1093/ecco-jcc/jjy004
- By:
- Publication type:
- Article
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 1, p. 105, doi. 10.1093/ecco-jcc/jjx117
- By:
- Publication type:
- Article
Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.
- Published in:
- Journal of Crohn's & Colitis, 2017, v. 11, n. 2, p. 246, doi. 10.1093/ecco-jcc/jjw137
- By:
- Publication type:
- Article
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
- Published in:
- Journal of Crohn's & Colitis, 2016, v. 10, n. 9, p. 1015, doi. 10.1093/ecco-jcc/jjw067
- By:
- Publication type:
- Article
High Anti-Tumour Necrosis Factor Trough Concentrations -- Only a Cost Issue or Also Hidden Dangers Ahead?
- Published in:
- Journal of Crohn's & Colitis, 2015, v. 9, n. 11, p. 943, doi. 10.1093/ecco-jcc/jjv146
- By:
- Publication type:
- Article
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 85, doi. 10.1007/s40259-021-00512-8
- By:
- Publication type:
- Article
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
- Published in:
- BioDrugs, 2021, v. 35, n. 6, p. 715, doi. 10.1007/s40259-021-00507-5
- By:
- Publication type:
- Article
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 453, doi. 10.1007/s40259-019-00366-1
- By:
- Publication type:
- Article
Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820971214
- By:
- Publication type:
- Article
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2013, v. 108, n. 6, p. 962, doi. 10.1038/ajg.2013.12
- By:
- Publication type:
- Article